Investors

Euronext Amsterdam: DSFIR

We're dsm-firmenich - innovators in nutrition, health, and beauty

As a high-value consumer ingredients leader, we’re making rapid progress on our strategic journey to resilient growth

Latest results - Q1 2026

Q1 2026 highlights

  • 4% LFL sales growth, with strong performance in Perfumery & Beauty
  • 2026-2028 action plan aimed at accelerating financial performance introduced at March 2026 Capital Markets Day
  • Dual listing of shares on SIX Swiss Exchange as of May 21, 2026
  • €500 million share buyback for capital reduction, launched March 12, 2026
  • FY 2026 outlook maintained

Why invest in dsm-firmenich

dsm-firmenich are innovators in nutrition, health, and beauty, bringing progress to life through solving the tension between what people individually want (the desirable), what we collectively need (the essential) and what the planet demands (the sustainable).

We are strategically placed to capitalise on the positive long-term mega trend of holistic well-being which is fuelling above-market growth opportunities in our three, synergistic BUs operating in nutrition, health, and beauty creating and innovating in an integrated way.

Demand for fragrances and beauty products has surged, with scent being a key purchase driver

 

Consumers are prioritizing healthy nutrition 

 

The share of spend on preventative health is increasing year on year 

 

Our purpose

dsm-firmenich brings together two iconic companies. We have deep roots and a bright future, with shared strengths and unrivaled expertise that drive positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

Latest news

  • Weekly progress on share repurchase program to cover share plans and reduce capital

    12 May 2026

    Weekly progress on share repurchase program to cover share plans and reduce capital

  • dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026

    7 May 2026

    dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026

  • dsm-firmenich Q1 2026 trading update

    6 May 2026

    dsm-firmenich Q1 2026 trading update

Contact Investor Relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.

Explore more
  • dsm-firmenich at a glance

    Who we are. Why we merged. Where we’re going.

  • Analyst coverage & consensus

    The sell-side analysts covering dsm-firmenich and latest Vara consensus figures.

  • Financial calendar

    A handy overview of the key dates in our financial calendar.

Stay up to date

Be the first to know about key news as we continue shaping the future and bringing progress to life.